Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 79 | 13 | 65 |
| Samples | 50 | 11 | 38 |
| Peptides | 42 | 8 | 34 |
Function
ARL2BP · ARF like GTPase 2 binding protein
ADP-ribosylation factor (ARF)-like proteins (ARLs) comprise a functionally distinct group of the ARF family of RAS-related GTPases. The protein encoded by this gene binds to ARL2.GTP with high affinity but does not interact with ARL2.GDP, activated ARF, or RHO proteins. The lack of detectable membrane association of this protein or ARL2 upon activation of ARL2 is suggestive of actions distinct from those of the ARFs. This protein is considered to be the first ARL2-specific effector identified, due to its interaction with ARL2.GTP but lack of ARL2 GTPase-activating protein activity. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 40 amino-acid changes on canonical ENST00000219204 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ARL2BP · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ARL2BP – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 2/98 2% | 0/0 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Endometrial Carcinoma | 0/42 0% | 2/612 0% |
| Colorectal Carcinoma | 2/143 1% | 8/3239 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Melanoma | 0/210 0% | 4/1899 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 3/1390 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 1/2534 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Head and Neck Carcinoma | 1/85 1% | 0/1574 0% |
| Gastric Carcinoma | 0/74 0% | 1/1809 0% |
| Glioma | 0/52 0% | 1/2127 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| Hepatocellular Carcinoma | 0/46 0% | 1/2210 0% |
| Breast Carcinoma | 0/144 0% | 1/3264 0% |
Mutation Distribution
Where ARL2BP is mutated · all tissues, split by cell line vs tissue
How many mutations in ARL2BP were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 79 mutations in ARL2BP
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|